Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q02985
UPID:
FHR3_HUMAN
Alternative names:
DOWN16; H factor-like protein 3
Alternative UPACC:
Q02985; B4DPR0; Q9UJ16
Background:
Complement factor H-related protein 3, also known as DOWN16 or H factor-like protein 3, plays a crucial role in the immune system's complement regulation. Its involvement is pivotal in maintaining immune homeostasis and preventing uncontrolled complement activation.
Therapeutic significance:
The protein's association with atypical hemolytic uremic syndrome, a condition marked by renal failure and thrombocytopenia, underscores its therapeutic potential. Understanding its role could lead to breakthroughs in treating this life-threatening disease.